Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates

分组1 - Fortress Biotech reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of -48.39% [1] - The company posted revenues of $16.41 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 13.66%, compared to $14.9 million in the same quarter last year [2] - Fortress Biotech has surpassed consensus revenue estimates two times over the last four quarters [2] 分组2 - The stock has underperformed the market, losing about 4.7% since the beginning of the year, while the S&P 500 gained 10% [3] - The current consensus EPS estimate for the coming quarter is -$0.24 on revenues of $19.88 million, and for the current fiscal year, it is -$1.29 on revenues of $103.09 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for the sector [8]